BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akino S, Ohashi H, Okano T, Takeuchi S, Kawakami T, Soma Y, Kadono T. Sudden elevation of plasma D-dimer levels induced by the combination therapy of dabrafenib and trametinib: Report of two cases. J Dermatol 2019;46:358-60. [PMID: 30719722 DOI: 10.1111/1346-8138.14798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Mukai K, Kamata M, Miyazaki M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Ishikawa T, Ohnishi T, Tada Y, Tanaka T. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma. J Dermatol 2021;48:707-9. [PMID: 33600004 DOI: 10.1111/1346-8138.15813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Nakamura Y, Ishizuki S, Iwasaki R, Okiyama N, Ishitsuka Y, Matsumura Y, Tanaka R, Maruyama H, Watanabe R, Fujisawa Y. Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events. J Dermatol 2020;47. [DOI: 10.1111/1346-8138.15163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]